Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. - Wikidata - wikimedia - TriplyDB

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

http://www.wikidata.org/entity/Q37769104

about

Alzheimer mechanisms and therapeutic strategies The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease 18 F-FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening Revolutionizing Alzheimer's disease and clinical trials through biomarkers A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers Homogeneous Biosensing Based on Magnetic Particle Labels A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates Platelets and Alzheimer's disease: Potential of APP as a biomarker Cognitive assessments for the early diagnosis of dementia after stroke An algorithmic approach to structural imaging in dementia Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases Personalized health care beyond oncology: new indications for immunoassay-based companion diagnostics A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease Magnesium protects cognitive functions and synaptic plasticity in streptozotocin-induced sporadic Alzheimer's model Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset Complexity of resting-state EEG activity in the patients with early-stage Parkinson’s disease The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Prediction and prevention of schizophrenia: what has been achieved and where to go next?Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.The link between cardiovascular risk, Alzheimer's disease, and mild cognitive impairment: support from recent functional neuroimaging studies.Close Correlation of Monoamine Oxidase Activity with Progress of Alzheimer's Disease in Mice, Observed by in Vivo Two-Photon Imaging Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease.Advances in MRI biomarkers for the diagnosis of Alzheimer's disease.Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline.Structural Neuroimaging of the Medial Temporal Lobe in Alzheimer's Disease Clinical Trials.Early intervention in Alzheimer's disease: a health economic study of the effects of diagnostic timing.Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease The EU-AIMS Longitudinal European Autism Project (LEAP): design and methodologies to identify and validate stratification biomarkers for autism spectrum disorders.Prediction of dementia in primary care patients.Application of a MRI based index to longitudinal atrophy change in Alzheimer disease, mild cognitive impairment and healthy older individuals in the AddNeuroMed cohort.A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease Multiple indices of diffusion identifies white matter damage in mild cognitive impairment and Alzheimer's disease.Can Functional Magnetic Resonance Imaging Improve Success Rates in CNS Drug Discovery?The future of blood-based biomarkers for Alzheimer's disease.Multi-method analysis of MRI images in early diagnostics of Alzheimer's disease Functional and structural MR imaging in neuropsychiatric disorders, part 2: application in schizophrenia and autism.

P2860

Q22252311-5C8BD848-0690-4C71-8918-5889259D66A1 Q22306292-4E3EB627-8C8D-4281-A5B1-B9BF58047AA7 Q24186399-7CFAC22D-7DD6-4800-84C8-07D22A5195A0 Q24594531-CCD7926A-45FE-4C2C-A746-5A6C018D2551 Q24630334-CE996A23-56E8-4B65-89EC-F6A91C7D85F4 Q26744882-91388148-626C-4964-84C6-FD9FC50F2200 Q26745508-181F5FE8-CB92-426D-8C42-AEB7E03B73DC Q26747505-946002DC-B658-4E40-AE21-7AD717128681 Q26786354-5DDC1D0F-DDAE-4BCB-95AE-B20EA9220BAE Q27001550-0C21C79B-BBF2-4A11-B072-ABB86A24E3E5 Q27010423-272A1295-54EB-4179-8029-EBB288664A2E Q27025567-CE307BC4-A152-4332-B9F6-0A5DB05A6471 Q27026884-26812AF3-B58B-43C8-A224-013ECF07A2EC Q28084590-CB17171F-41AB-45CB-BD7D-A227F3220C6F Q28252463-0F366322-6E75-4366-A9CB-193BC4F7A69D Q28543427-60E8BAFD-3DAB-4D86-85C4-E4D19B956C00 Q28595520-923CB2CC-452F-4CA9-B4D8-22D7C3641DC2 Q28730795-EDFD3BCF-3F90-4855-92BC-2B3C0E3801DF Q29048642-CC35E7E4-CD43-4DB4-A02C-567D725719BC Q29614406-1F93610A-8590-4272-9C1B-6DD193C011D9 Q30473765-C19BA9B5-E908-417F-9112-1FA2BA2823F9 Q30651551-967FBFB8-5ECA-4447-AD62-F15F9AB84526 Q30830414-ACE872BC-AFA5-494E-A54F-825C5795A111 Q30833430-53E5BB9A-A512-4245-8E1F-FE5E1A36549B Q30845482-944D2D89-B270-4F01-87B4-19D4F33517A7 Q30870223-6B65AFB0-3C82-4268-8C3C-9402896904BF Q30996727-88191B72-1025-4201-99CE-2B6BBF54FFFA Q30996733-D9575A15-AD36-42D5-8B3C-610A7D4E5473 Q33656133-9FEDD206-AFB6-43A8-B0D4-F3BBD00C2034 Q33666297-B7A1479B-6ACA-401B-AFB4-2DB9370C1E1E Q33822641-6F28F351-5412-4E7E-B800-1B24B82E10F9 Q33827324-E72088BF-590E-4D41-BEB8-6C9371FD1AC4 Q33833596-43FF4812-289A-4995-AA1F-2958947C288A Q33891581-3F2B77D5-2589-4661-9380-4C9969EC6DA3 Q33903249-1FAED927-E8A6-4870-BB20-E5FEE9CFDA9C Q33955354-FC803856-BB57-4F84-9BA9-F0ECBE710033 Q33963735-365EB77E-60D6-4627-BB1B-8F98E3196AA1 Q34026317-E92358B6-82BD-4270-B6F4-C38932F97E1E Q34055598-83CE01B3-0B5A-4CD6-9D57-C385838BF129 Q34102447-8C47CC73-5471-42C0-A0D8-19C1C5D975A4

P2860

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

http://www.wikidata.org/entity/Q37769104

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

@en

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

@nl

type

label

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

@en

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

@nl

prefLabel

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

@en

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

@nl

P1433

Q37769104-E4F89C2A-B6F5-4A2A-AF90-2446EF51CD8B

P1476

Q37769104-66AAB8EC-E770-497E-BD6A-46B372A0761E

P2093

Q37769104-0C557FEE-FAD0-420F-9261-3C0DB0CA2613

Q37769104-12013204-FCB9-4738-833F-78E3E5000223

Q37769104-1CF38986-19F9-48F8-9675-D84306EA29A1

Q37769104-208D77E4-DCD3-45A4-9C32-BF78A616CB4D

Q37769104-2ECE9928-F5E0-4DA1-A70F-5C7D5F5592FC

Q37769104-36CB1D9E-CE86-4208-9D4F-5D407BE377EE

Q37769104-8EC9E3E9-2738-4C28-9EE3-AB7A4E4CD87E

Q37769104-F76C950E-19E8-4740-B519-057A381A0D71

Q37769104-FE7EC4EC-FA70-486A-A60B-78D0F2157E57

P2888

Q37769104-32E2FC85-9DD1-4445-A7FD-FFF70246E849

P304

Q37769104-C0797BAC-CC45-4BBE-A0BE-486794A7ECDB

P31

Q37769104-B460BEEF-3C5B-4285-8256-3BB67E6D890D

P356

Q37769104-6C422EAB-366D-4D82-BF46-70093708C7C1

P433

Q37769104-278B0E51-E82E-4830-9282-00B8C546BA01

P478

Q37769104-854459D5-69B0-4E36-8375-75EE5E68F7A5

P50

Q37769104-265749F4-AEA0-4B3D-8FEE-12183EDFA6AA

Q37769104-64234DC8-1E4B-4610-A06B-11258BBF0C21

Q37769104-820884CE-FF46-4CE4-AA97-96CEC794B28C

Q37769104-FC1029C2-967D-41FE-8F6B-FB191D314AFC

Q37769104-FF411A94-2AD8-4F2C-8178-179919439D7B

P577

Q37769104-515B00CB-4B87-4CAB-A68F-74C7D0D2A853

P5875

Q37769104-EB0D15BB-AB76-4255-988A-3E6B74A2E26F

P698

Q37769104-BAA4A94C-68E8-4A32-A090-2C91AA987782

P921

Q37769104-17441B88-F402-4D93-B5D0-1E34D2D2E5BD

Q37769104-9CF19636-3EAC-4FDB-AFB3-7BA15161B05B

P356

P1433

Nature Reviews Drug Discovery

P1476

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

@en

P2093

Arun L W Bokde

http://www.w3.org/2001/XMLSchema#string

Frank Jessen

http://www.w3.org/2001/XMLSchema#string

Janet Woodcock

http://www.w3.org/2001/XMLSchema#string

Karl Broich

http://www.w3.org/2001/XMLSchema#string

Karl Herholz

http://www.w3.org/2001/XMLSchema#string

Richard Frank

http://www.w3.org/2001/XMLSchema#string

Russell G Katz

http://www.w3.org/2001/XMLSchema#string

Wendy R Sanhai

http://www.w3.org/2001/XMLSchema#string

Yvonne C Hoessler

http://www.w3.org/2001/XMLSchema#string

P2888

P304

560-574

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRD3115

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

John Anthony Hardy

Henrik Zetterberg

Stefan J Teipel

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44889506

http://www.w3.org/2001/XMLSchema#string

P698

20592748

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease